Search Follow us

EdisonTV

NeuroVive Pharmaceutical

EdisonTV | Pharmaceutical & healthcare | 24/04/2018

Bitesize briefing - NeuroVive Pharmaceutical

Mitochondrial disease is an umbrella term that includes a diverse set of conditions where the function of the mitochondria is failing. The diversity of the clinical presentation, low incidence rates and high unmet need make this an interesting area for specialist orphan drug developers. Here, healthcare analyst Dr Jonas Peciulis presents an overview of mitochondrial medicine, the competitive landscape in drug development and discusses one of the companies covered by Edison, specialising in the field, NeuroVive Pharmaceutical.

Read the report

Executive interview – ASIT Biotech

Executive interview – ASIT Biotech

ASIT Biotech is a Belgian biotechnology company focused on late-stage clinical development of allergy immunotherapies (AITs). Its first product in Phase III is a grass pollen AIT with the advantages of a very short administration. ASIT’s AITs require only four treatment visits in 3 weeks to the allergist prior to the pollen season rather than visits for most of the year which are needed with other subcutaneous AITs, or over many years for sublingual AITs. CEO, Thierry Legon, discusses the advantages of ASIT’s technology, its strong patent position and the timing for its next Phase III study, and the potential for ASIT’s technology platform to generate AITs in other allergy indications.
Watch »

16/07/2018 | ASIT Biotech

Executive interview - Kane Biotech

Executive interview - Kane Biotech

Kane Biotech (TSX-V: KNE, OTCQB: KNBIF) is taking a unique approach to addressing human and animal health by developing technology to break up biofilms, the glue-like substance secreted by microorganisms that prevent their removal. Biofilms are implicated in a range of health concerns from periodontal disease, medical device-associated infections, hospital-acquired infections and food safety.
Watch »

16/05/2018 | Kane Biotech

Bitesize briefing - NeuroVive Pharmaceutical

Bitesize briefing - NeuroVive Pharmaceutical

Mitochondrial disease is an umbrella term that includes a diverse set of conditions where the function of the mitochondria is failing. The diversity of the clinical presentation, low incidence rates and high unmet need make this an interesting area for specialist orphan drug developers. Here, healthcare analyst Dr Jonas Peciulis presents an overview of mitochondrial medicine, the competitive landscape in drug development and discusses one of the companies covered by Edison, specialising in the field, NeuroVive Pharmaceutical.
Watch »

24/04/2018 | NeuroVive Pharmaceutical

VolitionRx: Results from asymptomatic CRC trial reported

VolitionRx: Results from asymptomatic CRC trial reported

VolitionRx recently announced the initial results from a 680-sample study taken from asymptomatic colorectal cancer (CRC) patients. The study demonstrated 80% sensitivity against stage 1 CRC and 66% against high-risk adenomas (at 78% specificity). The company has stated that it is moving on to the 4,300-sample study to determine the final test panel for European launch (results in Q218). This will be followed by a 12,000+ sample blinded study which is expected to complete in H218.
Watch »

20/03/2018 | VolitionRx

VolitionRX reports their Full Year 2017 Earnings

VolitionRX reports their Full Year 2017 Earnings

VolitionRx Limited (VNRX:US), a multi-national life sciences company developing simple, easy to use blood-based cancer tests, today announced its Full Year 2017 earnings and will discuss this news as well as a business update on a conference call this morning. The company this week also announced interim results from a 680-Subject Clinical Trial in Colorectal Cancer.
Watch »

02/03/2018 | VolitionRx

Executive interview - Curetis NV

Executive interview - Curetis NV

Founded in 2007, Curetis is a developer of next-level molecular diagnostic solutions. Curetis focuses on the research, development and commercialisation of dependable, timely and cost-effective products that can be used to diagnose severe infectious diseases. The diagnostic achievements and progress the company is making enable rapid, multi-parameter pathogen and antibiotic resistance marker detection. It has designed the Unyvero platform, a fast, comprehensive diagnostics system that analyses severe infectious diseases in hospitalized patients. Using an array of cartridges, infectious diseases such as pneumonia or implant/tissue infections can be easily and rapidly diagnosed. While the current standard of diagnosis can take days or even weeks, Curetis can typically diagnose in four to five hours, either in a hospital laboratory or directly at the "point of need" in the intensive care unit.
Watch »

02/03/2018 | Curetis NV

VolitionRx Limited Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer

VolitionRx Limited Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer

VolitionRx Limited, a multi-national life sciences company developing simple, easy to use blood-based cancer tests, today announced interim results from a 680-subject clinical trial in colorectal cancer. The study demonstrates high detection rates of Stage I cancer and pre-cancerous adenomas in colorectal cancer using Volition’s Nu.Q™ blood test.
Watch »

26/02/2018 | VolitionRx

Executive Interview - NeuroVive Pharmaceutical (Part 2)

Executive Interview - NeuroVive Pharmaceutical (Part 2)

NeuroVive is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT) and one project in clinical Phase I (KL1333) for genetic mitochondrial diseases. Here, CEO Erik Kinnman speaks about the progress KL1333 has made over the past month – receiving orphan drug designation in Europe and the status of the first clinical trial.
Watch »

17/01/2018 |

Executive Interview - NeuroVive Pharmaceutical (Part 3)

Executive Interview - NeuroVive Pharmaceutical (Part 3)

NeuroVive is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT) and one project in clinical Phase I (KL1333) for genetic mitochondrial diseases. Here, CEO Erik Kinnman speaks about the progress KL1333 has made over the past month – receiving orphan drug designation in Europe and the status of the first clinical trial.
Watch »

15/12/2017 |

Executive interview - Genkyotex

Executive interview - Genkyotex

In this interview, Genkyotex CEO Mr Elias Papatheodorou explains the core technology of its business and the products it is developing. He provides an overview of the competitive advantages of Genkyotex’s products with respect to its competitors. Furthermore, he discusses the current landscape for fibrosis and the market opportunity for its products. Finally, he provides timelines for the next value inflection points.
Watch »

05/12/2017 | Genkyotex

Executive interview - TxCell

Executive interview - TxCell

TxCell offers a rare investment opportunity as it is the only company applying CAR-T technology to regulatory T-cells (Tregs) for autoimmune and inflammatory therapy. Tregs have very powerful control functions in the immune system. The first CAR-Treg studies are planned in transplantation starting in 2018, followed by possible trials in other indications like multiple sclerosis.
Watch »

30/11/2017 | TxCell

Executive Interview - NeuroVive Pharmaceutical

Executive Interview - NeuroVive Pharmaceutical

NeuroVive is a leader in mitochondrial medicine, with one project in clinical Phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT) and one project in clinical Phase I (KL1333) for genetic mitochondrial diseases. Here, CEO Erik Kinnman speaks about the company as it stands now and what the future holds for it.
Watch »

29/11/2017 | NeuroVive Pharmaceutical

Executive interview - Orgenesis

Executive interview - Orgenesis

• Orgenesis is a vertically integrated biopharmaceutical company with expertise and unique experience in cell therapy development and manufacturing. • Through its Israeli subsidiary, Orgenesis Ltd, Orgenesis is a pioneer in the development of technology designed to successfully reprogram human liver cells into glucose-responsive, fully functional, insulin producing cells (IPCs). • Its Belgian subsidiary, MaSTherCell, is a global Contract Development and Manufacturing Organization (CDMO), through which Orgenesis is able to deliver optimised process industrialisation capacities to cell therapy organizations, and speed up the arrival of their therapies onto the market.
Watch »

28/11/2017 | Orgenesis

Executive interview - VolitionRx

Executive interview - VolitionRx

An interview covering third quarter results and a business update with Cameron Reynolds, CEO of Volition, a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers.
Watch »

20/11/2017 | VolitionRx

Executive interview - Targovax

Executive interview - Targovax

In this short video Magnus Jaderberg, Chief Medical Officer of Targovax gives us some background on Targovax and discusses key technology areas.
Watch »

08/11/2017 | Targovax

Executive interview - NetScientific

Executive interview - NetScientific

NetScientific is a healthcare investment company with a focused portfolio of potentially disruptive biomedical and healthcare technology investments. The current focus is on digital health, diagnostics and therapeutics with the portfolio consisting of four core investments in which it has controlling stakes (Vortex, Wanda, ProAxsis and Glycotest) and one material investment (PDS). The aim is to bring these to commercialisation over the next two years, with the ultimate goal of an exit, realising value for investors.
Watch »

11/10/2017 | NetScientific

Executive interview - Race Oncology

Executive interview - Race Oncology

Race Oncology is developing bisantrene, which had been the subject of over 40 clinical trials in the 1980s and 1990s as part of Lederle’s search for a safer anthracycline chemotherapy. Despite positive responses in a variety of cancers, especially AML (it was even approved for the treatment of AML in France, but never commercialised), development stopped after Lederle was sold to Wyeth and then Wyeth to Pfizer. Race will be developing bisantrene initially for relapsed/refractory AML and expects to start a pivotal trial for approval in the US around the end of 2018.
Watch »

09/10/2017 | Race Oncology

VolitionRx announces second quarter 2017 financial results

VolitionRx announces second quarter 2017 financial results

Cameron Reynolds, president and CEO of VolitionRx explains: “We have had numerous highlights this quarter, with strong progress being made on many fronts. I am delighted with the growing strength of new talent in our team, especially the growth in our Research & Development team in Belgium. We are also fortunate to be working with institutions and individuals who have brilliant reputations. We continue to announce large trials, such as the recent signing of a 13,500-patient US trial in colorectal cancer. We believe that this most recently announced trial, with a cost to us of only $3m, represents an exceptional value for our money. We look forward to achieving additional milestones in the upcoming quarters and sharing further exciting news.”
Watch »

10/08/2017 | VolitionRx

Executive interview - 4SC

Executive interview - 4SC

4SC is a Munich-based cancer biopharmaceutical company. In this interview Jason Loveridge, CEO of 4SC, provides an overview of the company, its recent equity capital raise (€41m gross) and its updated and progressive development plan.
Watch »

10/08/2017 | 4SC

Executive interview - e-Therapeutics

Executive interview - e-Therapeutics

e-Therapeutics (ETX) is a UK-based drug discovery company that has developed a proprietary, computer-based discovery platform based on network biology. In this interview Dr Ray Barlow, CEO of e-Therapeutics, provides an overview of the company, and outlines the output of its recent strategic review and its focus moving forward.
Watch »

09/08/2017 | e-Therapeutics

Executive interview - Volition Rx

Executive interview - Volition Rx

Volition America, a wholly owned subsidiary of VolitionRx Limited, announces a major new colorectal cancer screening trial with 13,500 patients. In collaboration with the Great Lakes New England Clinical Validation Center and funded by the US National Cancer Institute’s (NCI) Early Detection Research Network (EDRN), this clinical study will seek to validate a panel of biomarkers that include Volition’s Nu.Q Colorectal Cancer Screening test in a large asymptomatic population to support US regulatory approval.
Watch »

18/07/2017 | VolitionRx